Several antibiotic drug developers are looking to alternative delivery systems to offer localized delivery for anti-infective agents – such as inhaled formulations that target the lungs – a pathway that could result in new approvals for older molecules.
Pulmonary delivery technology that could make new products from generic antibiotics has attracted a range of respiratory-focused companies to the...
Welcome to Scrip
Create an account to read this article
Already a subscriber?